196617-29-5

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 

Relevant academic research and scientific papers

Synthesis and structure elucidation of a copper(II) Schiff-base complex: In vitro DNA binding, pBR322 plasmid cleavage and HSA binding studies

New copper(II) complex with Schiff base ligand 4-[(2-Hydroxy-3-methoxy-benzylidene)-amino]-benzoic acid (H2L) was synthesized and characterized by spectroscopic and analytical and single crystal X-ray diffraction studies which revealed that the complex 1 exist in a distorted octahedral environment. In vitro CT-DNA binding studies were performed by employing different biophysical technique which indicated that the 1 strongly binds to DNA in comparison to ligand via electrostatic binding mode. Complex 1 cleaves pBR322 DNA via hydrolytic pathway and recognizes minor groove of DNA double helix. The HSA binding results showed that ligand and complex 1 has ability to quench the fluorescence emission intensity of Trp 214 residue available in the subdomain IIA of HSA.

Synthesis, characterization and biological evaluation of metal(ii) complexes containing triphenylphosphine and schiff base ligand based on 3-methoxysalicylaldehyde

Schiff base ligand (HL) derived from condensation of 3-methoxy salicylaldehyde with 4-aminobenzoic acid and its metal(II) complexes containing triphenylphosphine of the type [MCl(PPh3)(L)] (M = Ni2+, Co2+ or Cu2+; L = bitendate Schiff base ligand) have be

Synthesis, composition and use of novel therapeutic and cosmetic Schiff base products formed by reaction of a carbonyl containing moeity with a transimination nucleophilic catalyst and the use of transimination nucleophilic catalysts to increase the rate

The present invention relates to the synthesis, composition and use of novel moieties formed by reacting a transimination nucleophilic catalyst, molecular or polymeric, with carbonyl-containing therapeutic or cosmetic moieties. The resultant Schiff base p